Form 4: Baker Bros. Convert Non-Voting Shares to Ordinary Shares in Bicycle Therapeutics PLC

Baker Bros. Advisors LP converted non-voting ordinary shares of Bicycle Therapeutics PLC into ordinary shares in the form of American Depositary Shares (ADS) on June 17, 2024.

Summary

• On June 17, 2024, 667, L.P. and Baker Brothers Life Sciences, L.P. converted 196,098 and 2,186,686 non-voting ordinary shares, respectively, into ordinary shares in the form of American Depositary Shares (ADS).
• The conversion was done on a 1-for-1 basis without consideration.
• These non-voting ordinary shares were acquired prior to the May 29, 2024 offering of Bicycle Therapeutics plc.
• The holders can convert non-voting ordinary shares into ordinary shares at any time, subject to a beneficial ownership limitation.
• The beneficial ownership limitation restricts holders from owning more than 9.99% of the outstanding ordinary shares after conversion, although this limit can be increased to 19.9% with written notice to the issuer.
• Baker Bros. Advisors LP submitted written notice to increase the Beneficial Ownership Limitation from 9.99% to 19.9% on April 16, 2024, which became effective on June 16, 2024, related to the Pre-Offering Non-Voting Ordinary Shares.
• Another notice to increase the Beneficial Ownership Limitation from 9.99% to 19.9% on May 28, 2024, related to the May 2024 Non-Voting Ordinary Shares, will take effect on July 29, 2024.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing, indicating standard transactions. The sentiment is neutral, reflecting the expected actions of a major shareholder.

Positives

• The conversion of non-voting shares to ordinary shares could simplify the capital structure of Bicycle Therapeutics PLC.
• The increase in the beneficial ownership limitation allows Baker Bros. to potentially increase their stake in the company.

Risks

• The beneficial ownership limitation, even at 19.9%, could restrict Baker Bros.' ability to fully capitalize on potential upside in Bicycle Therapeutics PLC.
• The timing of the beneficial ownership limitation increase may impact Baker Bros.' trading strategy.

Future Outlook

The document indicates a planned increase in the beneficial ownership limitation for shares acquired in the May 2024 offering, set to take effect on July 29, 2024, suggesting a continued interest from Baker Bros. in increasing their stake in Bicycle Therapeutics PLC.

Industry Context

Form 4 filings are standard disclosures for significant shareholders, directors, and officers, providing transparency into their transactions in the company's securities. This filing indicates Baker Bros.' ongoing involvement with Bicycle Therapeutics PLC.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for insiders in publicly traded companies, ensuring transparency in their trading activities.
• The beneficial ownership limitation is a common mechanism used by investors to manage their ownership stake and avoid triggering certain regulatory thresholds.
• Similar conversions and adjustments to ownership limitations are frequently observed in the biotechnology sector, where institutional investors often hold significant positions.

Stakeholder Impact

• The conversion of shares and potential increase in ownership stake by Baker Bros. could influence investor sentiment towards Bicycle Therapeutics PLC.
• The transactions do not appear to have any immediate impact on employees, customers, suppliers, or creditors.

Next Steps

• The increase in the Beneficial Ownership Limitation on the May 2024 Non-Voting Ordinary shares will take effect on July 29, 2024.
• RSUs granted to Felix J. Baker will vest in three equal annual installments beginning on April 18, 2025, subject to his continuous service on the board.

Key Dates